We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+32.01%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$288M
AUM Growth
+$69.6M
Cap. Flow
+$25.3M
Cap. Flow %
8.77%
Top 10 Hldgs %
62.41%
Holding
37
New
13
Increased
8
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$17.2M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$15M
3
MRK icon
Merck
MRK
+$14.7M
4
BAX icon
Baxter International
BAX
+$12.9M
5
MRUS
Merus
MRUS
+$11.6M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$26M
2
GEHC icon
GE HealthCare
GEHC
+$13.3M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
CTLT
CATALENT, INC.
CTLT
+$11.8M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CATX icon
26
Perspective Therapeutics
CATX
$335M
$929K 0.32%
+78,030
New +$665K
FEMY icon
27
Femasys
FEMY
$9.09M
$47.4K 0.02%
1,530
-278
-15% -$7.3K
ABBV icon
28
AbbVie
ABBV
$435B
– –
-167,807
Closed -$26M
AZN icon
29
AstraZeneca
AZN
$250B
– –
-29,394
Closed -$3.96M
BIIB icon
30
Biogen
BIIB
$30.5B
– –
-45,814
Closed -$11.9M
GEHC icon
31
GE HealthCare
GEHC
$31.7B
– –
-171,676
Closed -$13.3M
IMTX icon
32
Immatics
IMTX
$1.34B
– –
-275,482
Closed -$2.9M
KVUE icon
33
PUT
Kenvue
KVUE
$37.8B
– –
-698,800
Closed -$15M
MLTX icon
34
MoonLake Immunotherapeutics
MLTX
$1.49B
– –
-47,604
Closed -$2.87M
SRRK icon
35
Scholar Rock
SRRK
$5.74B
– –
-207,147
Closed -$3.89M
VRNA
36
DELISTED
Verona Pharma
VRNA
– –
-293,112
Closed -$5.83M
CTLT
37
DELISTED
CATALENT, INC.
CTLT
– –
-261,797
Closed -$11.8M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Tri Locum Partners held 37 positions worth $288M, up 32% from $219M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Tri Locum Partners deployed $25.3M of net new capital in Q1 2024, opening 13 new positions and adding to 8 existing holdings. Its largest new stake was Silk Road Medical, Inc. Common Stock: 1,083,605 shares worth $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $7.08M trimmed.

  • Tri Locum Partners's largest Q1 2024 buy was Silk Road Medical, Inc. Common Stock: 1,083,605 shares worth $19.9M.
  • Tri Locum Partners added most to Legend Biotech in Q1 2024, an estimated $10.9M increase.
  • Tri Locum Partners's biggest Q1 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $7.08M.
  • Tri Locum Partners fully exited AbbVie in Q1 2024, selling an estimated $26M.
  • Tri Locum Partners's ten largest holdings make up 62% of its $288M portfolio in Q1 2024.
  • Tri Locum Partners opened 13 new positions and closed 10 in Q1 2024.
  • Tri Locum Partners's portfolio value rose 32% quarter-over-quarter to $288M.

Based on Tri Locum Partners's 13F filing for Q1 2024, filed 15 May 2024.